- Home
- ACRV vs ALIS Comparison
ACRV vs ALIS Comparison
Compare ACRV & ALIS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ACRV | ALIS |
|---|---|---|
| Founded | 2018 | 2024 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 82.2M | 85.0M |
| IPO Year | 2022 | N/A |
Fundamental Metrics
Financial Performance| Metric | ACRV | ALIS |
|---|---|---|
| Price | $1.56 | $10.12 |
| Analyst Decision | Buy | |
| Analyst Count | 4 | 0 |
| Target Price | ★ $11.67 | N/A |
| AVG Volume (30 Days) | ★ 343.3K | 15.0K |
| Earning Date | 05-08-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 15.13 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $568.17 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.15 | $9.87 |
| 52 Week High | $3.56 | $10.15 |
Technical Indicators
Market Signals| Indicator | ACRV | ALIS |
|---|---|---|
| Relative Strength Index (RSI) | 47.51 | 62.54 |
| Support Level | $1.56 | $10.05 |
| Resistance Level | $1.86 | N/A |
| Average True Range (ATR) | 0.08 | 0.02 |
| MACD | 0.01 | 0.00 |
| Stochastic Oscillator | 76.92 | 66.67 |
Price Performance
Historical ComparisonAbout ACRV Acrivon Therapeutics Inc.
Acrivon Therapeutics Inc is a clinical-stage biopharmaceutical company developing oncology medicines that the Firm matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's pipeline includes ACR-368, referred to as prexasertib, a targeted oncology asset, as well as preclinical stage pipeline programs targeting critical nodes in the DNA Damage Response and cell cycle regulation pathways, including WEE1, a protein kinase, and PKMYT1; ACR-2316 a selective, dual WEE1/PKMYT1 inhibitor; and ACR-6840, a development candidate targeting CDK11. It has one reportable segment focused on the research and development of precision oncology therapies.
About ALIS Calisa Acquisition Corp Ordinary shares
Calisa Acquisition Corp is a blank check company with the purpose of effecting a merger, asset acquisition, stock exchange, stock purchase, reorganization, or similar business combination.